Impact of Solanum Melongena Peel on Arsenic-Induced Bowen’s Disease

Article Sidebar

PDF
Published: Aug 27, 2025
DOI: https://doi.org/10.47191/ijpbms/v5-i8-07
Keywords:
Solanum melongena peel, Bowen’s disease, Arsenic

Main Article Content

Razia Sultana
Assistant professor, Department of Pharmacology, Monowara Sikder Medical College
Tasaduk Kabir
M.S Student, Bangladesh Agricultural University, Bangladesh
M Azizul Haq
Medical officer, ENT Care Center, Gulshan, Dhaka
Murtoza Shahriar
Resident Medical officer, Feni Cardiac Centre and Specialised Hospital
Nigar Jahan Sonia
Assistant professor, Department of Biochemistry, Marks Medical College and Hospital
Simonto Mirza
M.S Student, Department of Physical and Mathematical Sciences, Chattogram Veterinary and Animal Sciences University
Nakib Kamran Oni
Senior House officer, Emergency Department Barking, Havering and redbridge University Hospitals, NHS Trust

Abstract

Background with objective: About millions of Bangladeshi people are chronically exposed to high concentration of arsenic through contaminated drinking water and thus suffering from arsenic-related health hazards. In arsenicosis, skin manifestations like melanosis, leucomelanosis and keratosis occur commonly. In addition, it may cause Bowen’s disease. This study was conducted to confirm the effect of the ointment containing Solanum melongena peel extract in the treatment of arsenic-induced Bowen’s disease.


Methodology: This Observational comparative study was carried out among 08 arsenic induced Bowen’s disease patients at the Pharmacology department, Bangladesh Medical University (BMU), Dhaka and two arsenic affected endemic areas [Bhanga Upazilla of Faridpur District (about 150 km from Dhaka) and Babutipara Union, Muradnagar Upazilla, Cumilla District (about 108 km from Dhaka)] from September 2017 to January 2019. Purposive sampling was done according to availability of the patients. All the data were compiled and sorted properly and the quantitative data was analyzed statistically by using Statistical Package for Social Science.


Result: In patients with arsenic-induced Bowen’s disease, the mean (± SD) size of the lesions was 4.5 ± 2.9 cm2 before intervention and 2.7 ± 1.9 cm2after interventions. The percentage of reduction was 40. P-value was 0.027 for arsenic-induced Bowen’s disease. This result was statistically significant.


Conclusion: The present study reveals that S. melongena peel extract is effective in the treatment of clinically diagnosed, arsenic-induced Bowen’s disease.

Article Details

How to Cite
Razia Sultana, Tasaduk Kabir, M Azizul Haq, Murtoza Shahriar, Nigar Jahan Sonia, Simonto Mirza, & Nakib Kamran Oni. (2025). Impact of Solanum Melongena Peel on Arsenic-Induced Bowen’s Disease. International Journal of Pharmaceutical and Bio Medical Science, 5(08), 479–484. https://doi.org/10.47191/ijpbms/v5-i8-07
Issue
Vol. 5 No. 08 (2025): Volume 05 Issue 08 August 2025
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Yoshida, T., Yamauchi, H. and Sun, G.F., 2004. Chronic health effects in people exposed to arsenic via the drinking water: Dose–response relationships in review. Toxicology and Applied Pharmacology, vol. 198, pp. 243-52.

II. Neubert, T. and Lehmann, P., 2008. Bowen’s disease: A review of newer treatment options. Therapeutics and Clinical Risk Management, vol. 4, pp. 1085-95.

III. Holt, P.J.A., 1988. Cryotherapy for skin cancer: Results over a 5‐year period using liquid nitrogen spray cryosurgery. British Journal of Dermatology, vol. 119, pp. 231-40.

IV. Cox, N.H. and Dyson, P., 1995. Wound healing on the lower leg after radiotherapy or cryotherapy of Bowen's disease and other malignant skin lesions. British Journal of Dermatology, vol. 133, pp. 60-5.

V. Morton, C.A., Whitehurst, C., Moseley, H., McColl, J.H., Moore, J.V. and Mackie, R.M., 1996. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. British Journal of Dermatology, vol. 135, pp. 766-71.

VI. Ahmed, I., Berth‐Jones, J., Charles‐Holmes, S., O’Callaghan, C.J. and Ilchyshyn, A., 2000. Comparison of cryotherapy with curettage in the treatment of Bowen’s disease: A prospective study. British Journal of Dermatology, vol. 143, pp. 759-66.

VII. Salim, A., Leman, J.A., McColl, J.H., Chapman, R. and Morton, C.A., 2003. Randomized comparison of photodynamic therapy with topical 5‐fluorouracil in Bowen's disease. British Journal of Dermatology, vol. 148, pp. 539-43.

VIII. Bargman, H. and Hochman, J., 2003. Topical treatment of Bowen's disease with 5-fluorouracil. Journal of Cutaneous Medicine and Surgery, vol. 7, pp. 101-5.

IX. Yerebakan, Ö.,Ermis, O., Yilmaz, E. and Basaran, E., 2002. Treatment of arsenical keratosis and Bowen’s disease with acitretin. International Journal of Dermatology, vol. 41, pp. 84-7.

X. Rosen, T., Harting, M. and Gibson, M., 2007. Treatment of Bowen's disease with topical 5% imiquimod cream: Retrospective study. Dermatologic Surgery, vol. 33, pp. 427-32.

XI. Braathen, L.R., Szeimies, R.M., Basset-Seguin, N., Bissonnette, R., Foley, P., Pariser, D., Roelandts, R., Wennberg, A.M. and Morton, C.A., 2007. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: An international consensus. Journal of the American Academy of Dermatology, vol. 56, pp. 125-43.

XII. Daunter, B. and Cham, B.E., 1990. Solasodine glycoside. In vitro preferential cytotoxicity for human cancer cells. Cancer Letters, vol. 55, pp. 209-20.

XIII. Igarashi, K., Yoshida, T. and Suzuki, E., 1993. Antioxidative activity of nasunin in chouja-nasu (little eggplant, Solanum melongenaL.'chouja'). Nippon ShokuhinKogyo Gakkaishi, Vol. 40, pp. 138-43.

XIV. Noda, Y., Kneyuki, T., Igarashi, K., Mori, A. and Packer, L., 2000. Antioxidant activity of nasunin, an anthocyanin in eggplant peels. Toxicology, vol. 148, pp. 119-23.

XV. Nagase, H., Sasaki, K., Kito, H., Haga, A. and Sato, T., 1998. Inhibitory effect of delphinidin from Solanum melongena on human fibrosarcoma HT-1080 invasiveness in vitro. Planta Medica, vol. 64, pp. 216-9.

XVI. Cham, B.E., Daunter, B. and Evans, R.A., 1991. Topical treatment of malignant and premalignant skin lesions by very low concentrations of a standard mixture (BEC) of solasodine glycosides. Cancer Letters, vol. 59, pp. 183-92.

XVII. Dawe, S.A., Salisbury, J.R. and Higgins, E., 2005. Two cases of Bowen's disease successfully treated topically with 3% diclofenac in 2.5% hyaluronan gel. Clinical and Experimental Dermatology: Viewpoints in Dermatology, vol. 30, pp. 712-3.

XVIII. Sarah, Q.S. and Misbahuddin, M., 2018. Effect of Solanum melongena peel extract in the treatment of arsenic-induced Bowen’s disease. Bangladesh Journal of Pharmacology, vol. 13, pp. 309-15.